Oifig an Stiúrthóra Náisiúnta
Géaroibríochtaí

Aonad 4A, Áras Dargan, An Ceantar Theas,
An Bóthar Míleata, Cill Mhaighneann, Baile
Átha Cliath 8, D08 NN9V

Office of the National Director
Acute Operations

Unit 4a, the Dargan Building, Heuston
South Quarter, Military Road,
Kilmainham, Dublin 8, D08 NN9V

www.hse.ie
@hselive

t 01 795 9972
e acutehospitals@hse.ie

Deputy Colm Burke
Dáil Éireann
Leinster House
Dublin 2

21st September 2023

PQ 39003/23 - To ask the Minister for Health since the establishment of the rare diseases technology review committee (RDTRC) in 2018, the specific drugs that have been considered by the RDTRC and their recommendations, in tabular form; whether these drugs are now available to Irish patients; the timelines for each from EMA licence to availability; and if he will make a statement on the matter. -Colm Burke

Dear Deputy Burke,

The Health Service Executive has been requested to reply directly to you in the context of the above parliamentary question, which you submitted to the Minister for Health for response.

In order to respond to your Parliamentary Question, Acute Operations contacted the Rare Diseases Technology Review Committee (RDTRC).

In informing your PQ, the RDTRC advised:

The HSE Drugs Group may request Patient and Clinician Engagement input for a drug via the Rare Diseases Technology Review Committee (RDTRC) to assist the group in making a recommendation to the HSE Executive Management Team regarding reimbursement of said drug.

The RDTRC review all pertinent data available and facilitate Patient and Clinician Engagement. A statement is then issued from the RDTRC to the HSE Drugs Group for final decision making.

The RDTRC supplied the information on the included Excel file.

The file displays the drug considered, EMA License Data, the date the HSE Drugs Group requests RDTRC Engagement, the date the RDTRC delivers its statement to the HSE Drugs Group, the outcome on the RDTRC statement to HSE Drugs Group and the availability of the drug to Irish patients.

I trust this is of assistance to you.

Yours sincerely,

Caroline Lynch
General Manager
Acute Operations